Navigation Links
Epilepsy Therapy Project Announces "Shark Tank" Competition to Identify the Most Innovative, New Products for People with Epilepsy

WASHINGTON, Oct. 20, 2011 /PRNewswire-USNewswire/ -- The Epilepsy Therapy Project (ETP), a non-profit organization whose mission is to accelerate new therapies for people living with epilepsy and seizures and the parent organization of, today announced a "Shark Tank" competition and is now inviting entries that represent the most innovative ideas in epilepsy treatment and care. The winner of the 2012 Shark Tank competition will receive national recognition and a cash award supporting the development and commercialization of an important new product, technology or therapeutic concept. Epilepsy and seizure conditions affect more than 60 million individuals from infants and adults to accident victims and war veterans suffering from head injuries.

The top finalists will present their product concepts or therapeutic candidates at the Epilepsy Pipeline Update Conference in San Francisco on February 2, 2012.  The winning entry will be selected by a panel of judges representing physicians and scientists, corporate executives, industry investors, people with epilepsy and their family members. The project deemed to be the most innovative will be announced at the conclusion of the conference, and the winner will receive a $50,000 grant to accelerate the idea towards improving the quality of life of people with epilepsy. Finalists may be eligible for a travel stipend to attend the conference and will receive free conference registration. For more information and instructions on submitting a letter of intent, please visit or contact  

How to Submit Your Idea

Applicants must provide a letter of intent outlining their project goals and the near-term potential benefit to people with epilepsy, as well as the deliverables expected as a result of the grant.  Applicants must demonstrate an ability to move the proposed plan to completion, showing how the prize can accelerate any step along the path to market.

Some examples of novel and exciting concepts could fall into the following innovative categories:

  • A system to detect seizures with the capacity to provide early warning to the patient or family;
  • A treatment that stops a seizure from progressing;
  • A system that helps patients manage their daily treatment (for example an e-diary or pill reminder technology);
  • A device that prevents physical injury that patients may experience when in seizure; or
  • An entirely new product concept with the promise to dramatically improve the lives of people with epilepsy.  

Letters of intent are due by November 30, 2011. The finalists selected to present their projects at the conference will be notified by December 30, 2011.

"The Epilepsy Therapy Project is a powerful and committed supporter of groundbreaking epilepsy research with near-term applications, particularly in the advancement of new therapeutics and devices," said Warren Lammert, ETP Founder and Chairman. "This year, we are inaugurating the "Shark Tank" competition to spur scientists, clinicians, industrial design leaders and the epilepsy community to submit ideas with the promise to improve quality of life for people living with epilepsy every day. We are excited to sponsor this competition and look forward to receiving inventive new ideas with the potential to improve and even transform patient care."

The Third Biennial Epilepsy Pipeline Update Conference 2012 will be held on February 2-4, 2012, at the Hyatt Regency in San Francisco. This conference has earned recognition as the leading showcase for the most promising epilepsy therapies in development from entrepreneurs, startups and established companies dedicated to pioneering and advancing drugs, biologics, technologies and devices for epilepsy The 2012 conference has been expanded to three days to accommodate the unveiling of  the "Shark Tank" competition finalists' concepts and product candidates, and to include a day for people with epilepsy, family members and healthcare advocates focused on the importance and challenges of developing new therapies for epilepsy and seizure conditions.  

For additional information or to register for the Third Biennial Epilepsy Therapy Pipeline conference, please visit  

Early bird registration fees are available until November 30, 2011.

Corporate sponsorship opportunities are available.  Please contact or 540.687.8077, ext.100.

About the Epilepsy Therapy Project

The Epilepsy Therapy Project is a 501(c) (3) non-profit organization whose mission is to accelerate ideas into therapies for people living with epilepsy and seizures.  Founded in 2002 by a group of parents, distinguished physicians, and researchers, the Epilepsy Therapy Project supports the commercialization of new therapies through direct grants and investments in promising academic and commercial projects.  For more information about epilepsy, epilepsy treatment and the epilepsy pipeline, please visit our website, or call 540.687.8077.  

SOURCE Epilepsy Therapy Project
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Editor-in-Chief of Elseviers Epilepsy & Behavior presented with Ambassador for Epilepsy Award
2. NeuroSigma Receives Notice of Award from NIH for an STTR Grant for its Trigeminal Nerve Stimulation Therapy for Epilepsy
3. NeuroSigma Responds to Substantial Interest Generated by NPR Story on Promising Epilepsy Clinical Trial
4. Topiramate Exposure and Birth Defect Data to be Presented at the 29th International Epilepsy Congress
5. Texas Childrens Hospital Pioneers Use of MRI-guided Laser Surgery for Revolutionary New Epilepsy Treatment
6. Upsher-Smith Laboratories Begins Phase III Study of Intranasal Midazolam for Rescue Treatment of Seizure Clusters in Epilepsy Patients
7. Positive Results Reported for Phase II Randomized Double-Blind Clinical Trial for the Treatment of Drug-Resistant Epilepsy Using External Trigeminal Nerve Stimulation (eTNS™) - The USB Port to the Brain™
8. Upsher-Smith Laboratories Announces Initiation of Open-Label Extension Study of USL255 (Extended-Release Topiramate) for Adjunctive Treatment of Partial-Onset Epilepsy
9. Biopharma Company UCB Unveils 40 Deserving 2010 Family Epilepsy Scholarship Recipients
10. The Epilepsy Drug Market Will Remain Relatively Flat Through 2019 as Generic Erosion, Especially Within the Second-Generation Antiepileptic Drug Class, is Offset by the Launch of New Therapies
11. Cyberonics Announces Epilepsy Technology Agreements
Post Your Comments:
(Date:10/13/2015)... ) has ... European markets for Meniscal Repair - 16 Countries ... ) has announced the addition of ... Repair - 16 Countries (2010-2021)" report to ... ( ) has announced the addition of ...
(Date:10/13/2015)... , Oct. 13, 2015   Vigilant Biosciences, Inc. ... that aid in the early detection and intervention of ... Vigilant,s founder and CEO, Matthew H.J. Kim , ... which recognizes an entrepreneur who has made extraordinary contributions ... life sciences industry in the leadership of a company ...
(Date:10/13/2015)... , Oct. 13, 2015  EndoChoice Holdings, Inc. ... third quarter 2015 financial results on Thursday, November 5, ... . --> . ... Thursday, November 5, 2015 at 9:00 a.m. ET to ... for domestic callers and (412) 317-5469 for international callers. ...
Breaking Medicine Technology:
(Date:10/13/2015)... (PRWEB) , ... October 13, 2015 , ... ... hold the festivities in the friendly confines of their home. Whether it's making ... neighbors, try these Halloween recipes from Florida Dairy Farmers. , Recipe 1: ...
(Date:10/13/2015)... ... 2015 , ... Boulder native and lifelong athlete, Mark Gonglach, ... Tested by Olympic and professional athletes, he developed the combined massage and vibration ... sporting equipment and high-tech sales led him to transition from Rally Software to ...
(Date:10/13/2015)... ... October 13, 2015 , ... CURE Media ... today announced a new partnership with the International Waldenstrom’s Macroglobulinemia Foundation (IWMF) ... non-Hodgkin’s lymphoma, their families and physicians. , “Waldenstrom’s Macroglobulinemia is a so-called ...
(Date:10/13/2015)... ... 13, 2015 , ... According to an article published October 5th ... who successfully lose weight with a bariatric procedure are much less likely to develop ... notes that anywhere from 40 to 50 percent of all endometrial cancer cases are ...
(Date:10/13/2015)... ... October 13, 2015 , ... In an age where the ... 36 percent lower per square foot than in 2009. The Williamsport Regional Medical Center ... and cooling has decreased by eight percent. , According to Facilities Management Administrative ...
Breaking Medicine News(10 mins):